BR102015012091A8 - método para a preparação de uma solução de albumina humana, e, composição - Google Patents

método para a preparação de uma solução de albumina humana, e, composição

Info

Publication number
BR102015012091A8
BR102015012091A8 BR102015012091A BR102015012091A BR102015012091A8 BR 102015012091 A8 BR102015012091 A8 BR 102015012091A8 BR 102015012091 A BR102015012091 A BR 102015012091A BR 102015012091 A BR102015012091 A BR 102015012091A BR 102015012091 A8 BR102015012091 A8 BR 102015012091A8
Authority
BR
Brazil
Prior art keywords
solution
preparation
composition
human albumin
albumin
Prior art date
Application number
BR102015012091A
Other languages
English (en)
Other versions
BR102015012091A2 (pt
Inventor
Maria Ortiz Fernandez Ana
Ignacio Jorquera Nieto Juan
Costa Rierola Montserrat
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52003454&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR102015012091(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of BR102015012091A2 publication Critical patent/BR102015012091A2/pt
Publication of BR102015012091A8 publication Critical patent/BR102015012091A8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • C07K14/765Serum albumin, e.g. HSA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38Albumins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

método para a preparação de uma solução de albumina humana, composição, e, uso de uma composição. a presente invenção refere-se a um método para a preparação de uma solução de albumina humana, mais particularmente ela refere-se a um método compreendendo um estágio de redução do oxigênio dissolvido na dita solução de albumina até uma concentração igual a ou menor que 0,5 ppm. com o método da presente invenção é possível obter uma solução de albumina humana tendo um redox mais próximo do estado redox da albumina presente em plasma humano.
BR102015012091A 2014-05-29 2015-05-26 método para a preparação de uma solução de albumina humana, e, composição BR102015012091A8 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201430824A ES2524516B1 (es) 2014-05-29 2014-05-29 Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido

Publications (2)

Publication Number Publication Date
BR102015012091A2 BR102015012091A2 (pt) 2016-01-05
BR102015012091A8 true BR102015012091A8 (pt) 2021-03-16

Family

ID=52003454

Family Applications (1)

Application Number Title Priority Date Filing Date
BR102015012091A BR102015012091A8 (pt) 2014-05-29 2015-05-26 método para a preparação de uma solução de albumina humana, e, composição

Country Status (22)

Country Link
US (1) US10350274B2 (pt)
EP (1) EP2952203B9 (pt)
JP (3) JP2015224251A (pt)
KR (1) KR101960729B1 (pt)
CN (1) CN105315362B (pt)
AR (1) AR100618A1 (pt)
AU (1) AU2015202413B2 (pt)
BR (1) BR102015012091A8 (pt)
CA (1) CA2890642C (pt)
CL (1) CL2015001446A1 (pt)
ES (2) ES2524516B1 (pt)
HU (1) HUE031823T2 (pt)
IL (1) IL238898B (pt)
MX (1) MX362869B (pt)
MY (1) MY171771A (pt)
NZ (1) NZ708537A (pt)
PL (1) PL2952203T3 (pt)
PT (1) PT2952203T (pt)
RU (1) RU2657578C2 (pt)
SG (1) SG10201504137PA (pt)
TW (1) TWI607018B (pt)
ZA (1) ZA201503539B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2524516B1 (es) * 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
WO2017189919A2 (en) 2016-04-28 2017-11-02 Alkahest, Inc. Blood plasma and plasma fractions as therapy for tumor growth and progression
CN115957309A (zh) 2016-08-18 2023-04-14 万能溶剂有限公司 作为衰老相关认知障碍的治疗的血浆级分
AU2018257921B2 (en) 2017-04-26 2024-06-06 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
WO2020018343A1 (en) 2018-07-20 2020-01-23 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
CN109627322A (zh) * 2019-01-07 2019-04-16 中国科学院过程工程研究所 一种从Cohn组分Ⅴ上清中分离纯化人血清白蛋白的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4094965A (en) * 1977-04-01 1978-06-13 New England Nuclear Corporation Diagnostic agents containing albumin and method for making same
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
JPH07126182A (ja) * 1993-10-27 1995-05-16 Green Cross Corp:The 組換えヒト血清アルブミン製剤の滅菌方法
SE9402119D0 (sv) * 1994-06-16 1994-06-16 Pharmacia Ab Solution
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
JP4254117B2 (ja) * 2001-03-27 2009-04-15 ニプロ株式会社 アルブミン溶液収容プラスチック容器
EP1245217B1 (en) * 2001-03-27 2009-10-28 Nipro Corporation Plastic container containing albumin solution
WO2003002139A1 (fr) * 2001-06-29 2003-01-09 Asahi Kasei Kabushiki Kaisha Procede permettant d'ameliorer la stabilite de la preparation de proteines
US7252799B2 (en) * 2001-08-31 2007-08-07 Clearant, Inc. Methods for sterilizing preparations containing albumin
DE602004002834T2 (de) * 2003-08-28 2007-06-06 Nipro Corp., Osaka Künstlicher Sauerstoffträger und Herstellungsverfahren dafür
SI1986612T1 (sl) * 2006-02-07 2013-01-31 Shire Human Genetic Therapies, Inc. Stabilizirana spojina glukocerebrosidaze
ES2294976B1 (es) * 2007-11-12 2008-12-16 Grifols, S.A. "procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion".
JP5990880B2 (ja) * 2011-08-31 2016-09-14 東レ株式会社 有用タンパク質組成物およびその製造方法
CN102816230B (zh) * 2012-08-27 2014-02-12 同路生物制药股份有限公司 人血白蛋白的制备方法
ES2524516B1 (es) * 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido

Also Published As

Publication number Publication date
AU2015202413B2 (en) 2017-08-31
AU2015202413A1 (en) 2015-12-17
IL238898B (en) 2018-01-31
ES2601137T3 (es) 2017-02-14
US20150343025A1 (en) 2015-12-03
CN105315362A (zh) 2016-02-10
EP2952203A1 (en) 2015-12-09
KR20160024348A (ko) 2016-03-04
ES2524516B1 (es) 2015-03-31
MX2015006407A (es) 2015-11-30
ZA201503539B (en) 2017-01-25
EP2952203B1 (en) 2016-10-26
AR100618A1 (es) 2016-10-19
MX362869B (es) 2019-02-20
JP2020111614A (ja) 2020-07-27
CA2890642C (en) 2019-02-12
BR102015012091A2 (pt) 2016-01-05
US20170000855A9 (en) 2017-01-05
TW201544510A (zh) 2015-12-01
PL2952203T3 (pl) 2017-02-28
HUE031823T2 (en) 2017-08-28
NZ708537A (en) 2017-06-30
EP2952203B9 (en) 2018-03-14
SG10201504137PA (en) 2015-12-30
PT2952203T (pt) 2016-11-23
KR101960729B1 (ko) 2019-03-21
RU2015118453A (ru) 2016-12-10
RU2657578C2 (ru) 2018-06-14
CN105315362B (zh) 2019-10-25
JP2018115210A (ja) 2018-07-26
TWI607018B (zh) 2017-12-01
ES2524516A1 (es) 2014-12-09
CA2890642A1 (en) 2015-11-29
MY171771A (en) 2019-10-29
US10350274B2 (en) 2019-07-16
JP2015224251A (ja) 2015-12-14
CL2015001446A1 (es) 2016-05-13

Similar Documents

Publication Publication Date Title
BR102015012091A8 (pt) método para a preparação de uma solução de albumina humana, e, composição
BR112017008284A8 (pt) Bifidobactérias ativadas e métodos para uso das mesmas
BR112016010422A8 (pt) suplemento dietético, e uso de uma composição
BR112019000338A2 (pt) composições compreendendo cepas bacterianas
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
PE20180260A1 (es) Metodos y kits para tratar la depresion
BR112014026740A2 (pt) anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
BR112015029987A8 (pt) Beta-caseína a2 e a prevenção de inflamação do intestino
CL2016001076A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis.
BR112014030282A2 (pt) métodos de tratamento de excesso de peso e obesidade
GT201600002A (es) Bencil-1h-pirazolo[3,4-b]piridinas y su uso
EA202191513A1 (ru) Снижение вязкости фармацевтических составов
BR112013001301A2 (pt) processo para preparar uma composição líquida farmacêutica compreendendo imunoglobulina g humana e composição líquida farmacêutica contendo imunoglobulina g humana
BR112018003780A2 (pt) composições que compreendem um composto de urolitina
BR112015018360A2 (pt) terapia de combinação para o tratamento de pneumonia nosocomial
BR112013016590A2 (pt) uso de estabilizantes de glutamina
BR112016007487A2 (pt) composições compreendendo citrulina e leucina e seu uso no tratamento de diabetes e de síndrome meta-bólica
MX2016012559A (es) Composiciones de protector solar.
BR112014031841A2 (pt) formulação farmacêutica
BR112015022825A2 (pt) métodos de diagnóstico, seleção e tratamento de doenças e condições causadas por ou associadas a metanógenos
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
BR112015024703A2 (pt) formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose
BR102013030668A8 (pt) Composição para a preparação de ácido hialurônico reticulado viscoelástico e ácido hialurônico reticulado obtido por meio da utilização da mesma
BR112014024033A8 (pt) Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B03H Publication of an application: rectification [chapter 3.8 patent gazette]

Free format text: REFERENTE A RPI 2348 DE 05/01/2016, QUANTO AO ITEM (54)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2673 DE 29-03-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.